Nektar Therapeutics (Nasdaq: NKTR) today presented new data from the ongoing REZOLVE-AD Phase 2b study in a late-breaking ...
Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data ...
In severe asthma, more exacerbations occur November through January, with respiratory infection as the most commonly identified trigger.
The 2025 Lawrence and Nancy Golden Memorial Lectureship on Mind-Body Medicine focused on the psychobiology of asthma.
Omalizumab had the greatest risk for adverse effects and dupilumab had the most favorable safety profile among biologics for patients with asthma, according to an abstract presented at the CHEST ...
Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically ...
ARS Pharma to showcase a late-breaking oral presentation and six poster presentations highlighting real world impact of neffy ® (epinephrine ...
Uncontrolled inflammation is usually thought to be the culprit behind asthma. But in asthma patients who have survived ...
Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of ...
RedChip Companies will host an investor webinar with Connect Biopharma Holdings Limited (Nasdaq:CNTB) (Connect Biopharma, ...
An anti-inflammation injectable drug called dupilumab can reduce mucus buildup and improve breathing among asthma patients, a ...
Patients who depended on oral corticosteroids to care for their severe asthma experienced improvements in asthma control ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback